As on Thursday, Akero Therapeutics Inc (NASDAQ: AKRO) started slowly as it slid -3.49% to $44.03, before settling in for the price of $45.62 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $21.34-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -5.28%. Meanwhile, its Annual Earning per share during the time was -5.28%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.17%. This publicly-traded company’s shares outstanding now amounts to $79.92 million, simultaneously with a float of $70.67 million. The organization now has a market capitalization sitting at $3.52 billion. At the time of writing, stock’s 50-day Moving Average stood at $50.09, while the 200-day Moving Average is $43.03.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 11.65%, in contrast to 107.12% institutional ownership. According to the most recent insider trade that took place on Sep 02 ’25, this organization’s Chief Operating Officer sold 12,500 shares at the rate of 46.08, making the entire transaction reach 576,035 in total value, affecting insider ownership by 197,484. Preceding that transaction, on Aug 12 ’25, Company’s Chief Operating Officer sold 12,500 for 47.79, making the whole transaction’s value amount to 597,326. This particular insider is now the holder of 197,484 in total.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Akero Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 2.17% and is forecasted to reach -4.22 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -8.08% through the next 5 years, which can be compared against the -5.28% growth it accomplished over the previous five years trading on the market.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.80, a figure that is expected to reach -0.92 in the next quarter, and analysts are predicting that it will be -4.22 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Through scrutinizing the latest numbers posted by the [Akero Therapeutics Inc, AKRO], it can be observed that its last 5-days Average volume of 0.81 million was lower the volume of 1.37 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 12.24% While, its Average True Range was 27.70%.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 42.51%, which indicates a major rise in contrast to 13.53% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.85 that was lower than 2.26 volatility it exhibited in the past 100-days period.
